It’s imperative Canada keep pace with other competing jurisdictions, and establish itself as a regulatory leader that rewards investment and talent.
By Andrew Casey, President & CEO
Hill Times, September 18
The pandemic’s economic, social, and health impacts have effectively focused the attention of policymakers and the public on the strategic importance of building a competitive domestic life sciences industry and biomanufacturing capacity. Accordingly, nearly four years after the onset of the pandemic, all governments—including those in Canada—are prudently preparing for another pandemic or global health emergency. As a result, Canada’s biotech sector is having a generational moment on which we must capitalize.